Command Palette
Search for a command to run...
Medico Remedies
NSE: MEDICOBSE: 540937PHARMACEUTICALS & BIOTECHNOLOGYPHARMACEUTICALS
Market Cap
--
P/E Ratio
0.00
P/B Ratio
0.00
ROE
0.00%
ROA
0.00%
Debt/Equity
0.00
Book Value
₹0.0
EPS
₹0.0
About Medico Remedies
Medico Remedies is principally engaged in pharmaceutical business. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
Medico Remedies Limited was incorporated as a Private Limited Company as "Medico Remedies Private Limited" on March 18, 1994. The status was changed to a Public Company and the name of the Company was changed to Medico Remedies Limited on March 6, 2017. Medico Remedies is a pharmaceutical formulation manufacturing company with manufacturing and marketing capabilities in formulation with focus on anti-infective, Beta-Lactums, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, haematinics and other supplements. Further in addition to above, the Company also has manufacturing and marketing capabilities in other drugs such as NSAIDS, Antihistaminic, Antidiabetics, Cardio Vascular Drugs, Diuretics, Anti-Epileptics, combination drug kits, syrups and cream & gel for various therapeutic segments. The Company began its operations in 1994 with manufacturing and servicing of diuretics, anti-malarials, NSAIDS tablets, anti-reterovirals, anti-ulcer drugs and anti-acids tablets. Over the years the company has expanded its scale and scope of operations and currently the Company is engaged in manufacture of formulations for various medicines. As part of this expansion, in year 1999 & 2002, Company has a manufacturing facility for the manufacture of its products located in the State of Maharashtra at Palghar.. The plant is divided into two units, i.e. general formulations unit and beta-lactam unit; the beta lactam unit is further divided into two segments -Penicillin and Cephalosporins. The Company has built a strong relationship with its customers for drug formulations. The clients include Indian as well as foreign pharmaceutical companies like Anphar Limited, Saad Medical, Manfes Pharmaceuticals & Chemical Industries, Award Global Company Limited, Directorate of Health Services (DHS, Maharashtra) to name a few. The Company also earns revenue from the sale of licenses such as FMS license, FPS license and MESI license. In 2018-19, the Company purchased adjoining manufacturing unit with existing factory at Palghar. In January 2018, the Company came up with a Public Issue of 10,99,200 Equity Shares by raising equity capital amounting to Rs 10.99 Crores.
Price Action • MEDICO
Financial Statements
Consolidated & Standalone Reports
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 | Mar '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 175.78 | 153.63 | 147.05 | 144.38 | 123.05 | 123.42 | 90.73 | 99.59 | 61.94 | 54.78 | 66.92 | 51.1 |
Operating Expenses | 156.36 | 135.94 | 132.01 | 130.82 | 113.81 | 117.16 | 85.8 | 94.93 | 57.54 | 50.41 | 63.03 | 48.09 |
Operating Profit | 15.32 | 15 | 12.91 | 9.62 | 7.21 | 5.23 | 2.84 | 2.76 | 3.48 | 4.01 | 3.66 | 2.9 |
Operating Margin (%) | - | 9.77 | 8.78 | 6.66 | 5.86 | 4.24 | 3.13 | 2.77 | 5.62 | 7.32 | 5.47 | 5.68 |
Total Expenses | - | 140.13 | 135.71 | 134.29 | 116.5 | 119.73 | 88.52 | 97.41 | 60.06 | 52.79 | 65.05 | 50.16 |
EBITDA | - | 17.69 | 15.04 | 13.57 | 9.24 | 6.26 | 4.94 | 4.66 | 4.39 | 4.37 | 3.9 | 3.02 |
EBITDA Margin (%) | - | 11.52 | 10.23 | 9.4 | 7.51 | 5.07 | 5.44 | 4.68 | 7.09 | 7.98 | 5.83 | 5.91 |
Interest Expenses | 1.29 | 1.16 | 0.82 | 0.75 | 0.61 | 0.92 | 1.06 | 0.98 | 1.52 | 1.33 | 0.85 | 0.82 |
Depreciation | 3.03 | 3.03 | 2.88 | 2.72 | 2.08 | 1.65 | 1.66 | 1.51 | 1 | 1.05 | 1.18 | 1.25 |
Profit Before Tax (PBT) | 15.1 | 13.5 | 11.33 | 10.1 | 6.55 | 3.69 | 2.22 | 2.18 | 1.87 | 1.99 | 1.87 | 0.94 |
Tax Expenses | 3.76 | 3.41 | 3.04 | 2.86 | 1.66 | 1.09 | 0.58 | 0.6 | 0.65 | 0.06 | 0.74 | 0.31 |
PAT Before Extraordinary Items | - | 10.09 | 8.29 | 7.24 | 4.89 | 2.59 | 1.63 | 1.57 | 1.22 | 1.93 | 1.13 | 0.63 |
Net Profit | 11.35 | 10.09 | 8.29 | 7.24 | 4.89 | 2.59 | 1.63 | 1.57 | 1.22 | 1.63 | 1.13 | 0.79 |
Net Profit Margin (%) | - | 6.68 | 5.72 | 5.15 | 4.04 | 2.11 | 1.83 | 1.6 | 1.99 | 2.99 | 1.69 | 1.55 |
EPS (Adjusted) | - | 1.22 | 1 | 0.87 | 0.59 | 0.31 | 0.2 | 0.19 | 0.15 | 0.2 | 0.14 | 0.1 |
Valuation & Key Ratios
Performance Metrics
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 | Mar '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Per Share | - | 7.53 | 6.31 | 5.28 | 22.48 | 78.23 | 71.98 | 68.05 | 64.27 | 51.16 | 92.15 | 85.09 |
Return on Assets (ROA) % | - | 8.42 | 8.61 | 8.28 | 6.41 | 3.42 | 2.16 | 2.05 | 2.05 | 3.36 | 2.48 | 2.21 |
Return on Equity (ROE) % | - | 16.15 | 15.83 | 16.51 | 13.1 | 7.98 | 5.45 | 5.56 | 4.57 | 9.94 | 7.66 | 5.81 |
Return on Capital Employed (ROCE) % | - | 23.33 | 22.77 | 23.61 | 18.69 | 12.23 | 9.41 | 10.21 | 11.6 | 12.14 | 14.2 | 12.4 |
Profitability Ratios | - | - | - | - | - | - | - | - | - | - | - | - |
Liquidity Ratios | - | - | - | - | - | - | - | - | - | - | - | - |
Valuation Ratios | - | - | - | - | - | - | - | - | - | - | - | - |
Debt to Equity Ratio | - | 0.22 | 0.13 | 0.18 | 0.28 | 0.4 | 0.4 | 0.45 | 0.45 | 1.14 | 0.94 | 0.58 |
Featured Insight
No recent news available
Key People
H
Harshit Mehta
Chairman.,Executive Director,Whole Time Director,Chief Financial Officer
D
Dinesh Modi
Company Secretary,Compliance Officer
M
Ms. Shweta Mehta
Manager(Regulatory Affairs)
M
Mr. Rajesh C. Chawda
Chief Accountant(Accountant)
M
Mr. Nilesh Misal
Head Of The Department(Production,General Service)
M
Mr. Akhilesh Singh
Head Of The Department(Production)